Cyclacel's cancer drug sapacitabine gets FDA's orphan-drug status

07/1/2010 | Reuters

The FDA granted orphan-drug designation to sapacitabine, Cyclacel Pharmaceuticals' experimental drug for acute myeloid leukemia and bone marrow stem cell disorder. The drugmaker plans to proceed with pivotal late-stage trials of the product this year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY